Table 4. Factors predictive of rapid (RVR) and sustained virological response (SVR) to anti-hepatitis C virus therapy.

	Univariate nonparametric analysis				Multivariable analysis
					RVR		SVR
Factor	RVR (%)	P	SVR (%)	P	Adjusted OR (CI95)	P	Adjusted OR (CI95)	P
Plasma HCV RNA
(≤vs.>800000 IU/mL)	67.6 vs. 25.0	0.003	82.8 vs. 50.0	0.02	5.36 (1.04 – 27.81)	0.04	6.68 (1.01 – 47.08)	0.05
LDL-C mg/dL
(≥80 vs.<80)	70.0 vs. 33.3	0.02	88.9 vs. 47.4	0.008	3.08 (0.67 – 14.05)	0.14	3.31 (0.45 – 24.33)	0.23
Cirrhosis
(no vs. yes)	60.6 vs. 40.0	0.12	74.2 vs. 62.5	0.30	2.51 (0.51 – 12.23)	0.25
Use of TDF vs. ABV	54.5 vs. 60.0	0.49	72.4 vs. 87.5	0.35	n.a.		n.a.
IL28B
(CC vs. CT/TT)	43.5 vs. 42.1	0.26	63.2 vs. 68.4	0.50	n.a.		n.a.
Treatment exposition
(≥80% vs.<80%)	n.a.		81.6 vs. 40.0	0.07	n.a.		7.81 (0.37 – 161.4)	0.18

TDF: tenofovir. ABV: abacavir. n.a.: not applicable.